March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA
A year to the day after unveiling a $73 million series A round led by Omega Funds, immuno-oncology company Amunix Pharmaceuticals Inc. raised $117 million in a series B round led by Viking Global Investors with participation by new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, Clough Capital Partners and CaaS Capital Management, as well as several existing investors. Where the series A round supported Amunix’s pivot into drug development, the latest raise will help the company move its lead in-house program, AMX-818, a masked, protease-activated T cell engager (XPAT) targeting HER2-expressing solid tumors, into the clinic for solid tumors.
$157M series D for Thiel-backed atai
Atai Life Sciences AG raised $157 million in a series D round led by existing investors Apeiron Investment Group, the family office of atai founder Christian Angermayer, Thiel Capital and new investor Woodline Partners. Atai plans to use the funds in part to expand its pipeline of therapies for mental health disorders...